

Clomiphene Citrate as Nanomedicine Assistance in Ovulatory Disorders and Its Hyphenated Techniques [†]

Tejasweeni Girase ^{1,*}, Javesh Patil ^{2,*} , Aayushi Tatiya ¹, Devyani Patil ¹ and Mamta Patil ¹

¹ Department of Quality Assurance, PSG Vidya Prasarak Mandal's College of Pharmacy, Shahada 425409, India; aayushitatiya@gmail.com (A.T.); patil.devyani017@gmail.com (D.P.); mamtapatil2911@gmail.com (M.P.)

² Department of Pharmacognosy & Phytochemistry, PSG Vidya Prasarak Mandal's College of Pharmacy, Shahada 425409, India

* Correspondence: tejasweeni20@gmail.com (T.G.); javesh4u@gmail.com (J.P.); Tel.: +91-9669424536 (T.G.); +91-9923441004 (J.P.)

[†] Presented at the 4th International Online Conference on Nanomaterials, 5–19 May 2023; Available online: <https://iocn2023.sciforum.net/>.

Abstract: Nanotechnology has prompted new aspirations for managing modern human challenges. Furthermore, it has been utilized for aid in the prevention, diagnosis, and treatment of ovulatory disorders. Women with ovulatory issues may benefit from formulations using nanotechnology as an alternative possible treatment. Clomiphene citrate is a nonsteroidal, ovulatory stimulant that acts as a selective estrogen receptor modulator (SERM). It is a triphenyl ethylene stilbene derivative that is primarily used to trigger ovulation in female infertility cases where there is anovulation. Anovulatory infertility is most frequently caused by polycystic ovarian syndrome (PCOS), which is a gynecological endocrine disorder. Elevated serum concentrations of androgens, LH, and insulin are the main features of its endocrine profile. The primary goal of treating PCOS-related infertility is to increase the amount of FSH that is exposed to the ovary, either by antagonizing the estrogenic effects of clomiphene citrate in the hypothalamus or by directly affecting the ovary using recombinant follicle-stimulating hormone (FSH). In about 80% of treated individuals, ovulation is recovered by clomiphene citrate. In this review, we discuss the chemistry and pharmacology of clomiphene citrate, as well as the delivery of clomiphene citrate via nanosystems for improving solubility and limiting side-effects. The hyphenated techniques for analyzing and quantifying clomiphene citrate in solvents and biological samples are also overviewed.

Keywords: clomiphene citrate; nanomedicine; ovulatory disorder; PCOS; hyphenated techniques

check for
updates

Citation: Girase, T.; Patil, J.; Tatiya, A.; Patil, D.; Patil, M. Clomiphene Citrate as Nanomedicine Assistance in Ovulatory Disorders and Its Hyphenated Techniques. *Mater. Proc.* **2023**, *14*, 6. <https://doi.org/10.3390/IOCN2023-14505>

Academic Editor: Aurélien Deniaud

Published: 5 May 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Ovulatory disorders are a spectrum of conditions that have an impact on a woman's endocrine system and are a major contributor to female infertility. Polycystic ovary syndrome (PCOS) is a hormonal issue that affects women during their reproductive years [1]. Stein and Leventhal are generally acknowledged as the first researchers of polycystic ovarian syndrome; however, in 1721, Vallisneri, an Italian scientist, reported a married, infertile woman with shiny, white-surfaced ovaries the size of pigeon eggs. Formal diagnosis criteria were not offered or generally used until a PCOS meeting sponsored by the National Institutes of Health (NIH) in the early 1990s [2].

The compound currently known as clomiphene citrate was discovered in 1956 by Frank Palopoli and his colleagues in the Merrell Chemistry Department at the time. The initial outcomes of clomiphene's human clinical trials—at the time known as MRL-41—were published by Greenblatt et al. (1961) in the *Journal of the American Medical Association (JAMA)* in October 1961. It was the third drug to be submitted to the United States Food and Drug Administration (USFDA) for review in accordance with the regulations. In 1965,

a New Drug Application (NDA) was filed. Clomiphene was then approved in 1967, which marked the beginning of its prescription availability in the USA [3].

An emerging subject called nanomedicine combines medicine and nanotechnology to find novel treatments and enhance those that currently exist. Nanomedicine is the science and technology of applying molecular tools and insights into the human body at the nanoscale to identify, treat, and prevent disease and traumatic injury, ease pain, and maintain and improve human health. Over the past two decades, we have assisted in the translation of several nanomedicine applications into clinical practice, ranging from medical devices to nano-pharmaceuticals [4,5].

2. An Overview on Ovulatory Disorders

A major contributing factor to infertility is ovulatory disorders. Ovulatory disorder is a term used to describe a class of ailments in which ovulation does not occur, occurs infrequently, or occurs irregularly. The hypothalamic–pituitary–ovarian (H–P–O) axis often indicates episodic or chronic dysfunction, which is related to ovulatory problems in girls and women of reproductive age [6]. A lack of effectors and dysfunctional ovaries are the results of abnormalities in the hypothalamic pulsatile release of GnRH. Similar to this, pituitary dysfunction prevents the ovaries from being stimulated, which restricts ovulation and follicular development [7].

For timely ovulation, a very precise hormonal balance is needed, including estrogen, progesterone, luteinizing hormone, and follicle-stimulating hormone (release of egg from the ovary). Hormone imbalance is the primary cause of ovulation disorders. The adhesion of the embryo to the uterine lining can be interfered with by low levels of progesterone. It also raises the possibility of miscarriage. Infertility in women is also attributed to elevated amounts of estrogen [8].

Anovulation (no ovulation) is a disease where eggs do not mature adequately or have not been released from the follicles of ovaries. Oligo-ovulation is a disorder in which ovulation does not take place on a regular basis and the menstrual cycle may last longer than the typical cycle of 21 to 35 days [9].

The following conditions frequently lead to the ovulatory disorders:

- Polycystic ovary syndrome (PCOS; most common);
- Hypothalamic dysfunction (either hypothyroidism or hyperthyroidism);
- Premature ovarian failure [10].

Polycystic Ovary Syndrome (PCOS)

One of the most frequent endocrine disorders in women appears to be polycystic ovary syndrome (PCOS). Stein and Leventhal gave the first thorough description of the syndrome in 1935. It is defined by an endocrine condition that causes chronic anovulation and is characterized by elevated androgen production and abnormal gonadotropin secretion. It was previously thought to be a benign reproductive illness with the main clinical repercussions being hirsutism and infertility. It is now well known that PCOS has important metabolic effects connected to insulin resistance. In fact, PCOS is a significant contributor to type 2 diabetes mellitus (DM) in females. Thus, polycystic ovary syndrome is associated with significant reproductive, endocrine, metabolic, and cardiovascular morbidity [11].

Menstrual irregularity, such as oligomenorrhea, and indicators of hyperandrogenemia, such as hirsutism, acne, and/or obesity, are the defining clinical signs of PCOS [12].

The major abnormalities in this condition are as follows:

1. Abnormal morphology of the ovary, identified by a characteristic hyperechogenic enlarged central stroma and >9 small follicles of 2–9 mm diameter on transvaginal ultrasound examination of the ovaries;
2. Abnormal steroidogenesis, which mainly involves increased androgen production from the ovary and also includes increased progesterone and estradiol production;
3. Hyperinsulinemia, which is more strongly associated with anovulation than any other aspect of the syndrome;

- Abnormal gonadotrophin secretion, which is most frequently seen in women with PCOS as confirmed by ultrasound and is characterized by elevated serum LH concentrations. Women with anovulatory PCOS appear to have a functional deficit in the endogenous activity of FSH [13].

Currently, the 1990 NIH/NICHHD conference's criteria are usually followed to decide if a patient has PCOS by examining and confirming menstrual dysfunction, hyperandrogenism (hirsutism, acne, and androgenic alopecia), and/or hyperandrogenemia, along with the exclusion of other associated conditions such as hyperprolactinemia, nonclassical adrenal hyperplasia, or thyroid disease [14].

Clomiphene citrate (CC) treatment is a simple, economical, and efficient method of stimulating ovulation with no or few side-effects; it has been widely utilized as a first-line treatment for anovulatory PCOS. CC binds to estrogen receptors on the hypothalamus, exhibiting an antiestrogenic action. This triggers a gonadotropin-releasing hormone pulse that causes gonadotropin secretion from the anterior pituitary gland [15].

3. Drug Profile of Clomiphene Citrate

3.1. Physicochemical Properties

The IUPAC name of clomiphene citrate is 2-[2-chloro-1,2-diphenylethenyl]-phenoxy]-N,N-diethylethanamine-2-hydroxy-1,2,3-propanetricarboxylate with empirical formula $C_{26}H_{28}ClNO \cdot C_6H_8O_7$ and molecular weight 598.1. Clomiphene citrate is a white to pale-yellow, odorless powder which is freely soluble in methanol and slightly soluble in water [16].

From a chemical aspect, clomiphene is a triphenylene derivative that shows structural similarities with diethylboestrol. Two isomeric variants of clomiphene, cis and trans, are referred to as zuclomiphene and enclomiphene, respectively, in the current nomenclature. The racemic combination used in the commercial preparation contains 40% zuclomiphene and 60% enclomiphene [17]. Although enclomiphene is completely antiestrogenic, zuclomiphene exhibits moderate estrogenic and antiestrogenic effects. The ability of zuclomiphene to trigger ovulation is almost five times greater than that of enclomiphene. Figure 1 describes the isomers of clomiphene [18].




Figure 1. Enclomiphene and zuclomiphene as trans and cis isomers.

3.2. Pharmacology and Mechanism

Clomiphene acts as an ovulatory stimulant and is a selective estrogen receptor modulator (SERM). It exerts estrogenic and antiestrogenic effects by selectively binding to estrogen receptors in the brain, ovary, endometrium, and cervix. Moreover, it has a partial estrogen-agonistic effect in the hypothalamus, which inhibits estrogenic negative feedback and increases gonadotropin levels. It boosts luteinizing hormone and follicle-stimulating hormone secretion, raising serum levels of testosterone in the meantime. Moreover, it is employed as an adjuvant to minimize pituitary suppression [19].

After clomiphene administration in the follicular phase of the ovarian cycle, the pulse frequency of LH increases, indicating that the primary action of the medication is to stimulate pulsatile secretion of gonadotrophin-releasing hormone (GnRH) by the hypothalamus [20].

4. Clomiphene Citrate Nanomedicine Assistance

Nanotechnology has prompted new aspirations for managing modern human challenges. Furthermore, it has been utilized for aid in the prevention, diagnosis, and treatment of ovulatory disorders. Intriguing characteristics and abilities of nanomaterials include their capacity to attain desirable sizes, to cross biological barriers more quickly, to be more soluble, and to be more reactive [21]. Clomiphene citrate as a nanomedicine possesses and exhibits the below-described benefits.

4.1. Reduced Side-Effects

Any change in the expression of the genes that influence how the embryo and endometrium interact during implantation may result in implantation failure and eventually infertility. Induction of ovulation with clomiphene citrate can have a number of negative effects, including antiestrogenic activity on the endometrium and the potential suppression of endometrial receptivity. Hence, nanosized formulations might be used as an alternate treatment. The influence of clomiphene citrate on the expression of genes involved in implantation and blood levels of estradiol were both improved by the drug's sustained release formulation, which also raised its targeting effectiveness. Thus, to lessen clomiphene citrate's negative effects on the endometrium, a novel nanosized CC-encapsulating PBF (Phosal-based formulation) has been developed. Prior research indicated that phospholipids, one of the major constituents of Phosal-based formulation (PBF), can be utilized to improve therapeutic efficacy and lower the overall dose needed, as well as prevent adverse effects and protect drugs against hydrolysis. Moreover, phospholipids shield the drugs from being degraded in the digestive system. This PBF could react better in implantation and avoid abortion by boosting genes involved in implantation. The formulation of PBF may offer potential substitutes to existing formulations for the oral administration of lipophilic drugs without any negative effects on non-target tissues [22].

4.2. Increased Solubility

One of the key factors in achieving the required drug concentration in the bloodstream for pharmacological response is solubility. The bioavailability and eventually solubility of drug molecules determine their effectiveness in treating a certain disease. A significant tool in this endeavor is nanotechnology. The drug clomiphene citrate has a moderate water solubility, but the use of nanotechnology has improved its solubility. Poorly soluble drugs can now be developed as nanosuspensions, either independently or in combination with other pharmaceutical excipients, because of recent developments in nanoparticle engineering. Pure drug particles colloidal dispersed at submicron (nanometer) sizes in an external liquid phase are known as nanosuspensions. When the saturation solubility and the surface area available for dissolution increase, nanosuspensions emerge as a well-organized and efficient method of drug delivery for compounds that are not water-soluble. It was attempted to improve the dissolution and solubility profile of clomiphene citrate using biodegradable polymers (chitosan and PLGA). However, no significant results were found. Subsequently, nanosuspensions were created using PVP K-30 and Tween-80. The nanosuspension (FF6) made via the solvent diffusion method using combinations of PVP K-30 (polymer) and Tween-80 (stabilizer) exhibited the highest improvement in solubility and in vitro drug release [23].

5. Hyphenated Techniques

Pharmaceutical analysis represents one of the most crucial aspects of drug development because it is required at all stages of the process, which calls for precise and reliable analytical method. An analytical method analyzes a sample qualitatively, quantitatively, or

structurally for one or more analytes using a specific technique and detailed, step-by-step instructions. Analytical methods are primarily intended to ascertain the identity, purity, and effectiveness of drug substances or pharmaceutical formulations [24]. Technology, chemistry, and physics advancements have introduced numerous analytical and chemical procedures while also facilitating the expansion of currently employed ones. Hyphenated techniques are created through the technological fusion of various analytical methods, including separation methods (mainly chromatography) and detection methods (mainly spectroscopy) [25]. Analytical methods for the analysis of clomiphene citrate are listed in Table 1, where SP refers to stationary phase (i.e., column) and MP refers to mobile phase.

Table 1. Table of analytical methods for determination of Clomiphene citrate.

Method	Chromatographic Condition	Reference
RP-HPLC	SP: Shimadzu C18 column MP: methanol/acetonitrile (90:10) Flow rate: 1.0 mL/min Detection wavelength: 295 nm Retention time: 3.44 min	[26]
LC-MS	SP: Luna C18 column MP: methanol/water containing 0.05% trifluoroacetic acid (70:30) N-didesmethyltamoxifen as internal standard Flow rate: 1 mL/min <i>m/z</i> : 406.3 and 344.3 Retention time: zuclomiphene, 3.35 min; enclomiphene, 4.04 min; N-didesmethyltamoxifen, 5.66 min	[27]
RP-HPLC	SP: Thermo cyano C18 column MP: acetonitrile/0.05 M phosphate buffer (60:40) (pH 3 by OPA) Flow rate: 1 mL/min Detection wavelength: 245 nm Retention time: 2.61 min	[28]

6. Conclusions

This study provided comprehensive information on clomiphene citrate's nanotechnological advancements, as well as all analytical methods for CC assessment in different chemical and biological matrices. This thorough review of the literature led to the conclusion that researchers can easily adapt the existing methods to suit their own needs.

Author Contributions: Conceptualization, T.G. and J.P.; writing—original draft preparation, T.G.; writing—review and editing, J.P. and T.G.; visualization, T.G. and M.P.; resources, T.G. and A.T.; data curation, T.G. and D.P.; supervision, J.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors would like to convey their obligation to Management and Principal, P.S.G.V.P. Mandal's College of Pharmacy, Shahada, Dist. Nandurbar.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Azziz, R. Polycystic Ovary Syndrome. *Obstet. Gynecol.* **2018**, *132*, 321–336. [CrossRef]
2. Szydłarska, D.; Machaj, M.; Jakimiuk, A. History of discovery of polycystic ovary syndrome. *Adv. Clin. Exp. Med.* **2017**, *26*, 555–558. [CrossRef]
3. Dickey, R. Development, pharmacology and clinical experience with clomiphene citrate. *Hum. Reprod. Update* **1996**, *2*, 483–506. [CrossRef]
4. Girase, T.; Patil, A.; Pawar, S.; Tatiya, A.; Patel, K. Review on Nanomedicines: A Smarter approach. *World J. Pharm. Pharm. Sci.* **2022**, *11*, 702–713.
5. Patil, J.; Sayyed, H.; Suryawanshi, H.; Patil, B. Formulation and Evaluation of Verdant Tablets Containing Saponin-Coalesced Silver Nanoparticles Got from Fenugreek Seed Extract. *Chem. Proc.* **2022**, *8*, 56. [CrossRef]
6. Munro, M.G.; Balen, A.H.; Cho, S. The FIGO ovulatory disorders classification system. *Int. J. Gynecol. Obstet.* **2022**, *159*, 1–20. [CrossRef]
7. Stewart, J.; Bhattacharya, S.; Hamilton, M. Ovulatory disorders. In *Management of Infertility for the MRCOG and Beyond*, 3rd ed.; Cambridge University Press: Cambridge, UK, 2014; pp. 31–44. [CrossRef]
8. Sharma, S.; Khinchi, M.P.; Sharma, N.; Agrawal, D.; Gupta, M.K. Female infertility: An overview. *Int. J. Pharm. Sci. Res.* **2011**, *2*, 1.
9. Adamson, G.D.; Baker, V.L. Subfertility: Causes, treatment and outcome. *Best Pract. Res. Clin. Obstet. Gynaecol.* **2003**, *17*, 169–185. [CrossRef]
10. Mikhael, S.; Punjala-Patel, A.; Gavriloja-Jordan, L. Hypothalamic-Pituitary-Ovarian Axis Disorders Impacting Female Fertility. *Biomedicines* **2019**, *7*, 5. [CrossRef]
11. Dunaif, A.; Thomas, A. Current Concepts in the Polycystic Ovary Syndrome. *Annu. Rev. Med.* **2001**, *52*, 401–419. [CrossRef]
12. Coughlan, C.; Ledger, W. Polycystic ovarian syndrome. In *Ovarian Stimulation*, 1st ed.; Cambridge University Press: Cambridge, UK, 2010; pp. 87–102. [CrossRef]
13. Homburg, R. The management of infertility associated with polycystic ovary syndrome. *Reprod. Biol. Endocrinol. RBE* **2003**, *1*, 109. [CrossRef]
14. Asunción, M.; Calvo, R.M.; San Millán, J.L.; Sancho, J.; Avila, S.; Escobar-Morreale, H.F. A Prospective Study of the Prevalence of the Polycystic Ovary Syndrome in Unselected Caucasian Women from Spain1. *J. Clin. Endocrinol. Metab.* **2000**, *85*, 2434–2438. [CrossRef]
15. Takasaki, A.; Tamura, I.; Okada-Hayashi, M. Usefulness of intermittent clomiphene citrate treatment for women with polycystic ovarian syndrome that is resistant to standard clomiphene citrate treatment. *Reprod. Med. Biol.* **2018**, *17*, 454–458. [CrossRef]
16. McLeish, M.J. Clomiphene Citrate. In *Analytical Profiles of Drug Substances and Excipients*; Elsevier: Amsterdam, The Netherlands, 1998; Volume 25, pp. 85–120. [CrossRef]
17. Sovino, H.; Sir-Petermann, T.; Devoto, L. Clomiphene citrate and ovulation induction. *Reprod. Biomed. Online* **2002**, *4*, 303–310. [CrossRef]
18. Ernst, S.; Kite, G.; Cantrell, J.S.; Richardson, A.; Benson, H.D. Stereochemistry of geometric isomers of clomiphene: A Correction of the Literature and a Reexamination of Structure-Activity Relationships. *J. Pharm. Sci.* **1976**, *65*, 148–150. [CrossRef]
19. MbiFeh, M.K.; Wadhwa, R. Clomiphene. StatPearls Publ. Published Online January 2022. Available online: <https://www.ncbi.nlm.nih.gov/books/NBK559292/> (accessed on 9 March 2023).
20. Sir, T.; Alba, F.; Devoto, L.; Rossmanith, W. Clomiphene Citrate and LH Pulsatility in PCO Syndrome. *Horm. Metab. Res.* **1989**, *21*, 583. [CrossRef]
21. Javid-Naderi, M.J.; Mahmoudi, A.; Kesharwani, P.; Jamialahmadi, T.; Sahebkar, A. Recent advances of nanotechnology in the treatment and diagnosis of polycystic ovary syndrome. *J. Drug Deliv. Sci. Technol.* **2023**, *79*, 104014. [CrossRef]
22. Ajdary, M.; Keyhanfar, F.; Aflatoonian, R. Design and evaluation of a novel nanodrug delivery system for reducing the side effects of clomiphene citrate on endometrium. *DARU J. Pharm. Sci.* **2020**, *28*, 423–432. [CrossRef]
23. Mohammadharun, M.M. Solubility enhancement of clomiphene citrate using nanotechnology. *World J. Pharm. Pharm. Sci.* **2017**, *6*, 530–561. [CrossRef]
24. Rudrapal, M.; Kothawade, A.P.; Ezzat, S.M.; Egbuna, C. Bioanalysis: Methods, techniques, and applications. In *Analytical Techniques in Biosciences*; Elsevier: Amsterdam, The Netherlands, 2022; pp. 1–24. [CrossRef]
25. Awuchi, C.G.; Twinomuhwezi, H. Hyphenated techniques. In *Analytical Techniques in Biosciences*; Elsevier: Amsterdam, The Netherlands, 2022; pp. 125–145. [CrossRef]
26. Sayare, A.S.; Undre, P.B.; Ghode, P.D.; Singh, S.V.; Ghode, S.P. Development and Validation of RP-HPLC Method for the Estimation of Clomiphene Citrate in Pharmaceutical Dosage Form. *Res. J. Pharm. Technol.* **2021**, *14*, 3483–3488. [CrossRef]
27. Crewe, H.K.; Ghobadi, C.; Gregory, A.; Rostami-Hodjegan, A.; Lennard, M.S. Determination by liquid chromatography–mass spectrometry of clomiphene isomers in the plasma of patients undergoing treatment for the induction of ovulation. *J. Chromatogr. B* **2007**, *847*, 296–299. [CrossRef]
28. Vaghasiya, N.; Paghadar, B.; Mahajan, T. Development and validation of first order derivative spectrophotometric method for estimation of clomiphene citrate in bulk drug and formulation. *Int. J. Res. Pharm. Nano Sci.* **2013**, *2*, 107–114.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.